# A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Source: https://onco.cc/trials/proceade-crc-03/  
OnCo record `proceade-crc-03` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Precemtabart tocentecan in colorectal cancer, now recruiting.

## Summary

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) is a phase 3 interventional study registered as NCT07549412, led by EMD Serono Research & Development Institute with Merck KGaA, Darmstadt, Germany, and recruiting on the registry. Official title: A Randomised, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03). Planned enrolment is 1020 participants (estimated). The study started in 2026-05-06 and primary completion is expected in 2029-10-16. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: PROCEADE-CRC-03
- Tags: ctgov-ingest
- Registry id: NCT07549412
- Phase: 3
- Setting: A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- Sponsor: EMD Serono Research & Development Institute
- Enrolled: 1020

## Sources

- ClinicalTrials.gov NCT07549412: https://clinicaltrials.gov/study/NCT07549412

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Precemtabart tocentecan](https://onco.cc/drugs/precemtabart-tocentecan/)
- companies: [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/)

---
JSON: https://onco.cc/api/v1/entities/proceade-crc-03.json